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جتربة عشوائية الستخدام دواء امليزوبروستول بالفم مقارنة بإجراء الشفط اخلوائي 
اليدوي لعالج اإلجهاض غري املكتمل يف مستشفى ثالثي املستوى يف نيجرييا
كيهيند فيمي اإيبيمي، منريالدين اأديرمي اإيجايا، كيكيلومو تيميلول اأدي�سينا
abstract: Objectives: This study aimed to compare the efficacy of oral misoprostol with manual vacuum aspir- 
ation (MVA) in first trimester incomplete abortions. Methods: This randomised controlled trial study was conducted 
at the University of Ilorin Teaching Hospital, Ilorin, Nigeria between April 2014 and November 2015. Pregnant 
women who presented with clinical features of incomplete abortion at a gestational age of 13 weeks or less were 
included. Patients who had profuse vaginal bleeding, an intrauterine device in situ, signs of pelvic infections or who 
were younger than 18 years old and had no accompanying adults to give informed consent were excluded. A total 
of 200 participants were randomly and equally allocated to either the MVA or misoprostol treatment group. The 
treatment group were given 600 µg of misoprostol orally. The primary outcome measure was complete uterine evac- 
uation, while secondary outcome measures included the need for additional surgical evacuation for failed treatment, 
adverse effects/complications, acceptability of and satisfaction with the treatment. Results: Both misoprostol and 
MVA had high complete evacuation rates, yet MVA was significantly higher (99% versus 83%, relative risk [RR]: 0.84, 
confidence interval [CI]: 0.766–0.918; P <0.001). Significantly more women in the misoprostol group required additional 
MVA for failed treatment than in the MVA treatment group (17% versus 1%, RR: 16.67, CI: 2.260–12.279; P <0.001). 
No significant difference was found between the misoprostol and MVA treatment groups in terms of satisfaction 
(92.7% versus 89.8%, RR: 1.04, CI: 0.946–1.127; P = 0.473). Conclusion: Treatments with misoprostol and MVA had 
high complete uterine evacuation rates, as well as high rates of acceptability and satisfaction. However, MVA had a 
significantly higher complete evacuation rate than misoprostol.
Keywords: Misoprostol; Abortion Techniques; First Trimester; Incomplete Abortion; Nigeria.
امللخ�ص: الهدف: هدفت هذه الدرا�سة اإىل مقارنة فعالية دواء امليزوبرو�ستول الذي يتناول عن طريق الفم مع اجراء ال�سفط اخلوائي اليدوي لعالج 
الإجها�ض غري املكتمل خالل فرتة احلمل الأوىل. الطريقة: اأجريت جتربة مقارنة ع�سوائية الإنتقاء يف م�ست�سفى جامعة اإيلورين التعليمي، يف 
نيجرييا يف الفرتة ما بني اإبريل 2014 ونوفمرب 2015، �سملت الدرا�سة ن�ساءاً حوامل يحملن اأعرا�ض �رسيرية لإجها�ض غري مكتمل يف عمر 
احلمل املبكر اأي 13 اأ�سبوًعا اأو اأقل، مت تخ�سي�ض ما جمموعه 200 م�ساركة اخرتن ب�سكل ع�سوائي ووزعن اإما ملجموعة العالج باإجراء ال�سفط 
اليدوي اأو عن طريق اإعطاء دواء امليزوبرو�ستول، اأعطيت جمموعة العالج الدوائي 600 ميكروغرام من امليزوبرو�ستول عن طريق الفم، كان 
مقيا�ض النتيجة الأويل هو الإخالء الكامل للرحم بعد العالج، يف حني ت�سمنت مقايي�ض النتائج الثانوية احلاجة اإىل اإخالء جراحي اإ�سايف 
للعالج الأويل الغري ناجح والآثار اأو امل�ساعفات، كما مت درا�سة قبول العالج ون�سبة الر�سا. النتائج: كان لكل من دواء امليزوبرو�ستول واإجراء 
ال�سفط اخلوائي اليدوي معدلت اإخالء رحم تامة بن�سب عالية، لكن الن�سبة كان اأعلى بكثري يف الإجراء اليدوي، اأي بن�سبة )%83 لالإجراء اليدوي 
مقابل %99 للدواء، ]CI[  ،0.84 = ]RR[ = 0.766–0.918؛ P >0.001(. احتاج عدد اأكرب بكثري من الن�ساء يف جمموعة امليزوبرو�ستول اإىل 
عالج اإ�سايف بنف�ض الإجراء ب�سبب عدم جناح العالج الأويل مقارنة مع جمموعة عالج جمموعة عالج ال�سفط اليدوي )بن�سبة %17 مقابل %1،
CI ،16.67 = RR = 2.260–12.279؛ P >0.001( مل يكن هناك فرق كبري بني جمموعات العالج بدواء امليزوبرو�ستول وال�سفط اليدوي من 
من حيث معدل الر�سا )%92.7 مقابل CI ،1.04 = RR ،89.9% = 0.946–1.127؛ P = 0.473(. اخلال�صة: كان العالج بدواء امليزوبرو�ستول 
والـعالج باإجراء ال�سفط اخلوائي اليدوي فاعاًل لإجالء للرحم بالكامل ومعدلت القبول والر�سا، مع ذلك كان معدل الإخالء الكامل اأعلى ب�سكل 
وا�سح يف جمموعة ال�سفط اليدوي من جمموعة دواء امليزوبرو�ستول.
الكلمات املفتاحية: امليزوبرو�ستول؛ طرق الإجها�ض؛ ف�سل احلمل الأول؛ اإجها�ض غري مكتمل؛ نيجرييا.
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Advances in Knowledge
- Misoprostol and manual vacuum aspiration (MVA) had high complete evacuation rates in first trimester incomplete abortion 
treatment.
- MVA had a significantly higher complete evacuation rate than misoprostol.
- There was a high satisfaction rate in both the misoprostol and MVA treatment groups.
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Complications arising from spontaneous and unsafe induced abortions have been recog- nised worldwide as a major public health concern 
and are one of the leading reasons women seek emergency 
care.1 A 2014 World Health Organization systematic ana- 
lysis estimated that 7.9% of all maternal deaths are due 
to abortion; however, this figure is lower than the previous 
estimate of 13%.2 Unsafe abortions are prevalent in 
countries with limited resources, where abortion laws 
are restrictive and/or access to safe abortion services 
is difficult.2
In sub-Saharan Africa, access to post-abortion care 
(PAC) services, especially treatment of incomplete preg- 
nancy terminations, is a priority.3 A major advancement 
in PAC services has been the use of manual vacuum 
aspiration (MVA) for uterine evacuation when uterine 
size is consistent with or ≤12 weeks of gestation.4 How- 
ever, research has shown that there is insufficient use, 
inadequate access to and low availability of uterine 
evacuation services in Nigeria.5
Medical treatment of incomplete abortion with 
misoprostol is an effective alternative to MVA or sharp 
curettage.6–10 Most studies comparing MVA with miso- 
prostol have shown that the former is more effective, 
but both have a high success rate.11,12 However, weeks 
et al.’s study contradicts this; 600 µg of oral misoprostol 
was found to be more effective than MVA (96.3% versus 
91.5%, respectively).13 Misoprostol is cheap, safe, heat- 
stable, easy to store and requires no surgical skills to admin- 
ister, making it attractive for use in sub-Saharan Africa.1,7,14 
Misoprostol use for incomplete abortions could decrease 
the burden on healthcare facilities and skilled surgical 
providers while also reducing the need for surgical equip- 
ment, supplies, anaesthesia and cutting costs to health- 
care systems worldwide.6 These features make misoprostol 
an important alternative to MVA in PAC. At the Univ- 
ersity of Ilorin Teaching Hospital, Ilorin, Nigeria, MVA 
was the traditional treatment for first trimester incom- 
plete miscarriage. This study aimed to compare the out- 
comes of oral misoprostol with MVA in first trimester 
incomplete abortion treatment at the University of Ilorin 
Teaching Hospital in Nigeria.
Methods
This randomised controlled trial was done at the 
Gynaecological Emergency Ward and Gynaecology 
Outpatient Clinic of the Department of Obstetrics 
and Gynaecology at the University of Ilorin Teaching 
Hospital, between April 2014 and November 2015 (trial 
code: PACTR201803003087264).
The subjects were pregnant women who had pres- 
ented at the Gynaecological Emergency Ward with clin- 
ical features of incomplete abortion at a gestational age 
of ≤13 weeks. Gestational age was calculated from the 
patient’s last menstrual period to the time of miscarr- 
iage. Incomplete abortion was defined as past or present 
history of vaginal bleeding during index pregnancy, 
open cervical os, history of passing tissue and/or positive 
urinary pregnancy test with evidence of substantial 
debris in the uterus on transvaginal ultrasound. Patients 
with profuse vaginal bleeding, an intrauterine device 
in situ or signs of pelvic infections or younger than 
18-years-old and had no accompanying adults to provide 
informed consent were excluded.
The participants were equally allocated to either 
the MVA or misoprostol treatment group by computer- 
generated random numbers using the Stat Trek© random 
number generator.15 The misoprostol group was labelled 
as treatment one and MVA was labelled treatment two. 
The upper limit of random numbers input into the Stat 
Trek© random number generator was 200 (reflecting 
the sample size), with a minimum value of one and a 
maximum of two, representing the two groups; it allowed 
for duplicate entries. Thereafter, a statistician created a 
table of 200 entries and labelled each entry with either 
number one or two. Participants’ assigned number one 
were allocated to the misoprostol group and those 
assigned number two were part of the MVA group.
A tag was attached to each patient’s folder to indi- 
cate the assigned treatment group for easy subsequent 
identification and follow-up. The participants, resear- 
chers and data analysers therefore were not blinded to 
the allocation. From the calculated sample size using a 
power of 80%, each group in the study consisted of 100 
subjects giving a total of 200 subjects, including a 10% 
attrition rate. Appropriate corrections were affected after 
the research instrument was pretested. Following the 
treatment, all patients were observed in-hospital for six 
hours before being discharged.
Participants allocated to the misoprostol group 
were given 50 mL of water with 600 µg of oral miso-
prostol. Participants allocated to the MVA group under- 
went the procedure (Ipas, Chapel Hill, North Carolina, 
USA) after intramuscular administration of 60 µg of 
pentazocine and 0.5 mg of ergometrine. The authors or 
research team resident doctors performed the proced- 
ures in an emergency ward operating theatre. 
Application to Patient Care
- Healthcare providers can prescribe misoprostol as a good alternative to MVA for treatment of first trimester incomplete abortion in 
limited resource countries in order to improve post-abortion care service availability and accessibility.
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This study employed a verbal rating scale translated 
into Yoruba that was applicable for the study participants 
to assess the severity of abdominal pain (0 = no pain, 1 = 
mild pain, 2 = moderate pain, 3 = severe pain, 4 = excru- 
ciating pain). Women were not routinely given analgesics 
based on the unit protocol for pain management.
Participants were observed for six hours—foll- 
owing misoprostol administration or the MVA proced- 
ure—before being discharged from the hospital. During 
this observation period, any products of conception at 
the cervical os were removed during speculum exam- 
ination. Patients were also monitored for side effects of 
misoprostol, including vaginal bleeding, headache, skin 
rash, abdominal pain, pyrexia (temperature ≥37.5°C), 
chills, nausea, vomiting, headache, diarrhoea and comp- 
lications of MVA such as uterine perforation. Vaginal 
bleeding was visually assessed based on patients’ reports 
as either absent, mild, moderate or severe. During the 
observation period, an interviewer administered a quest- 
ionnaire to the participants in both groups to assess 
adverse effects, pain and blood loss. Adverse effects were 
treated according to standard pain management prot- 
ocols. Prior to discharge, the participants were given 
the names and contact details of the researchers and 
research assistants in case of complications or if they 
wanted more information about their treatment. Packed 
cell volume was estimated one week before and after 
treatment in each group.
Follow-up appointments at the Gynaecological 
Clinic were scheduled for one-week post-procedure for 
women in both groups to confirm their abortion status or 
in case of complications. All women underwent ultra- 
sound assessment irrespective of their symptoms and 
clinical findings. Transvaginal ultrasound was used for 
further assessment due to its sensitivity. The same team 
of radiologists performed the ultrasound investigations 
at diagnosis and follow-up. Transvaginal ultrasound 
findings of an anteroposterior diameter of >1.5 cm was 
regarded as significant debris. 
In this study, treatment failure was defined as inc- 
omplete uterine evacuation warranting additional MVA 
based on persistent vaginal bleeding and/or ultrasound 
findings indicating significant debris. In such a situation, 
a sample was sent for histological evaluation. At the one-
week post-treatment follow-up, all participants were 
asked a series of questions on the treatment’s adverse 
effects, acceptability and their satisfaction.
Data were analysed using Statistical Package for the 
Social Sciences (SPSS), Version 21.0 (IBM, Corp., Armonk, 
New York, USA). The primary outcome measure was 
complete uterine evacuation, while secondary outcome 
measures included the need for additional surgical evac- 
uation, adverse drug effects/surgical complications and 
satisfaction with treatment. Levels of statistical signif-
icance were tested via a Chi-square test, a Mann-Whitney 
U test, Student’s t-test and by calculating relative risk (RR) 
with a 95% confidence interval (CI) applied as appropriate. 
A value of P <0.05 was considered statistically significant. 
The Ethical Committee of the University of Ilorin 
Teaching Hospital approved the study (ERC PAN/2014/ 
01/1264). Participants gave informed consent and their 
data were treated confidentially. The participants did not 
bear any service costs and no incentive was provided 
in any form.
Results
A total of 238 subjects were screened for eligibility, of 
which 200 subjects satisfied the inclusion criteria and 
subsequently 100 participants were allocated to each 
group in the study. In total, 38 subjects were excluded 
from the study because of excessive vaginal bleeding 
(n = 23) or refusal to participate (n = 15). In the miso- 
prostol group, four patients made unscheduled visits to 
the hospital 3–4 days after treatment due to bleeding 
per vaginam and therefore were assigned to the treatment 
failure category. Two MVA patients were lost to follow-up 
and were therefore excluded from the analysis [Figure 1]. 
The baseline demographic and reproductive variables 
were similar in both groups [Table 1]. Mean gestational 
age at miscarriage for the misoprostol and MVA groups 
 
Figure 1: Flow of participants through the enrolment, 
allocation, follow-up and analysis stages of the study.
MVA = manual vacuum aspiration.
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were 8.13 ± 1.45 and 8.17 ± 1.14 weeks, respectively 
(P = 0.832).
The misoprostol and MVA groups had high com- 
plete evacuation rates; however, MVA had a significantly 
higher rate (83% versus 99%, RR: 0.84, CI: 0.766–0.918; 
P <0.001). MVA had a significantly higher complete 
evacuation rate than misoprostol in the 8–10 weeks’ 
gestational age group [Table 2]. 
Significantly more participants in the misoprostol 
group required additional MVA for treatment failure 
than in the MVA group (17% versus 1%, RR: 16.67, 
CI: 2.260–12.279; P <0.001) [Table 3]. Of the 17 (17%) 
participants in the misoprostol group who required add- 
itional treatment, eight (47.1%) participants had products 
of conception in the debris sample. Significantly higher 
proportions of participants in the MVA group exp-
erienced moderate to severe abdominal pain than in 
the misoprostol group (99% versus 33.3%, RR: 0.34, 
CI: 0.254–0.447; P <0.001). However, more partic-
ipants in the misoprostol group had moderate to severe 
vaginal bleeding than in the MVA group (29.2% versus 
12.2%, RR: 2.30, CI: 1.346–4.590; P <0.001). Pyrexia 
was the most common adverse effect (40.6%) in the 
misoprostol group, followed by nausea (12.5%), chills 
(7.3%) and vomiting (6.3%); in the MVA group, nausea 
(7.1%) and vomiting (4.1%) were the most common 
adverse effects. Both misoprostol and MVA groups had 
high satisfaction rates (92.7% versus 89.8%, RR: 1.04, 
CI: 0.946–1.127; P = 0.473). Most participants in both 
groups expressed the desire to choose the respective 
method again and would recommend that method to 
their friends [Table 3].
Discussion
In the current study, the complete uterine evacuation 
rate was high in both the misoprostol and MVA groups, 
with MVA having a significantly higher success rate (83% 
versus 99%; P <0.001). This finding is in agreement with 
other studies in Burkina Faso, Tanzania, Ghana, Finland 
and Ecuador.10–12,14,16 The success rate of 600 µg oral 
misoprostol in this study was comparable with findings 
from varying dosages and routes of administration of 
misoprostol used in other studies.8,17,18 Similarly, a recent 
Cochrane Database Systematic Review that compared 
different routes of administration of misoprostol with 
MVA showed no clear evidence to suggest that one 
regimen was superior to another.19 Contrary to this and 
Table 1: Characteristics of patients who had been given oral 
misoprostol and/or manual vacuum aspiration in first trim- 
ester incomplete abortions at the University of Ilorin Teaching 
Hospital, Ilorin, Nigeria (N = 200)
Characteristic n (%) P 
value*
Misoprostol MVA Total 
Age group in years
≤19 5 (5) 0 (0) 5 (2.5) 0.074
20–24 21 (21) 12 (12) 33 (16.5) 0.117
25–29 38 (38) 44 (44) 82 (41) 0.508
30–34 23 (23) 32 (32) 55 (27.5) 0.225
≥35 13 (13) 12 (12) 25 (12.5) 0.842
Mean ± SD 28.38 ± 5.51 28.44 ± 3.31 - 0.93†
Occupation
Housewife 9 (9) 3 (3) 12 (6) 0.083
Student 9 (9) 5 (5) 14 (7) 0.285
Employed 76 (76) 84 (84) 160 (80) 0.527




3 (3) 2 (2) 5 (2.5) 0.655‡
Secondary 
education
9 (9) 6 (6) 15 (7.5) 0.438
Post-secondary 
education
7 (7) 9 (9) 16 (8) 0.617
Post-graduate 
education
81 (81) 83 (83) 164 (82) 0.876
Marital status
Married 91 (91) 94 (94) 185 (92.5) 0.825
Single 5 (5) 3 (3) 8 (4) 0.480
Unwed 
partnership
4 (4) 3 (3) 7 (3.5) 0.706
Estimated gestational age in weeks
5–7 36 (36) 32 (32) 68 (34) 0.628
8–10 62 (62) 68 (68) 130 (65) 0.599
11–13 2 (2) 0 (0) 2 (1) 0.157
MVA =manual vacuum aspiration; SD = standard deviation.
*Using Chi-square test.  †Using independent samples t-test. ‡Yates correction.
Table 2: Primary outcome measures of first trimester 
incomplete abortions using oral misoprostol and manual 
vacuum aspiration (N = 200)






































RR = relative risk; CI = confidence interval; MVA = manual vacuum 
aspiration. 
*Two women were lost to follow-up in the MVA group and were not 
included. 
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other findings, Weeks et al.’s study in Uganda found a 
slightly higher success rate among the misoprostol group 
than the MVA group, although the difference was not 
statistically significant (96.3% versus 91.5%; P = 0.43).13 
This study shows that MVA is more effective than 
misoprostol in treatment of incomplete abortion in the 
8–10 week gestational age group. However, treatment 
outcomes of MVA and misoprostol depended on 
providers’ skills and quality of the misoprostol.
The higher failure rate and need for MVA in this 
study could be due to the use of transvaginal ultrasono- 
graphy to assess complete emptiness of the uterine cavity 
as opposed to abdominal ultrasonography and clinical 
assessment used for post-intervention evaluation in 
other studies.10,11,20 However, transvaginal ultrasonography 
is more sensitive than abdominal ultrasonography and 
clinical assessment.21
This study, as has been observed in another study, 
demonstrated higher cases of pyrexia, nausea and chills 
among the misoprostol versus the MVA group.19 These 
symptoms are common side effects of misoprostol, 
with pyrexia being the most common side effect as a 
result of the drug’s action (prostaglandin E1 analogue) 
on the central thermoregulatory centre.22 MVA was 
identified as more painful than misoprostol, which is in 
agreement with Shwekerela et al. and Bique et al.’s studies 
but in contrast with Niinimäki et al.’s findings.10,12,23 Miso- 
prostol causes uterine cramping and bleeding during 
expulsion of the remaining products of conception; 
however, these side effects are transient and tolerable.
As in other studies, the current participants indic- 
ated high satisfaction with both misoprostol and MVA.9,11,16 
This finding was contrary to a study by Shwekerela et al., 
where the misoprostol group had a significantly higher 
percentage of participant satisfaction than the MVA 
group (75% versus 55%; P = 0.001).10 A comparably high 
percentage of participants in both groups in this study 
expressed a desire to recommend their treatment method 
to a friend and would use the same approach again, which 
is in-line with the findings of Dao et al.11 In contrast, 
Shwekerela et al.’s study determined that a significantly 
higher proportion of participants in the misoprostol 
group would recommend the treatment to a friend than 
in the MVA group (95% versus 75%; P <0.001).10 Niinimäki 
et al.’s study found that fewer participants in the miso- 
prostol group expressed a desire to choose the same treat- 
ment method in the future because of pain.12
Limitations of this study included the subjective 
visual estimation of vaginal bleeding and the small sample 
size; hence, it was difficult to assess the significance of 
some outcomes that were of low occurrence. 
Table 3: Secondary outcome measures of first trimester inc- 
omplete abortions using oral misoprostol and manual vacuum 
aspiration (N = 200)





































































































































































RR = relative risk; CI = confidence interval; MVA = manual vacuum aspiration.
*Four women in the misoprostol group who made an unscheduled visit and 
two women lost to follow-up in the MVA group were not included.
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Conclusion
Both misoprostol and MVA had high rates of satisfac- 
tion and complete uterine evacuation, which could ulti- 
mately reduce maternal death from abortion. However, 
MVA had a significantly higher complete evacuation rate 
than misoprostol. Misoprostol is cheap, readily available 
and does not require any surgical equipment or expertise. 
Therefore, healthcare providers should be encouraged 
to prescribe misoprostol for treatment of first trimester 
incomplete miscarriage as a form of task-shifting in 
limited resource countries and to improve the availability 
and accessibility of PAC services. 
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